Amino- and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions

Endocrinology

Volumn 144, Issue 7, 2003, Pages 2797-2806

  Payet, Louis D ^a   Wang, Xiu Hong ^a   Baxter, Robert C ^a   Firth, Sue M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTIDINE DERIVATIVE; HYBRID PROTEIN; PROTEIN SUBUNIT; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN RECEPTOR;

AFFINITY LABELING; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; IODINE RADIOISOTOPES; PEPTIDE FRAGMENTS; PRECIPITIN TESTS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2;

EID: 0038675358     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-0102     Document Type: Article

References (50)

1. Baxter RC 2000 Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol 278:E967-E976
2. Clemmons DR 2001 Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev 22:800-817
3. Baxter RC, Martin JL 1989 Structure of the M, 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity labeling. Proc Natl Acad Sci USA 86:6898-6902
4. Fowlkes JL, Thrailkill KM, George-Nascimento C, Rosenberg CK, Serra DM 1997 Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs)-3, -5, and -6 inhibit IGFBP-4 degradation. Endocrinology 138:2280-2285
5. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR 1998 Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol 275:E321-E331
6. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P 2000 Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-α regulate transcriptional signaling and apoptosis. J Biol Chem 275:33607-33613
7. Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P 2001 Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 86:1806-1813
8. Firth SM, Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854
9. Oh Y, Muller HL, Pham H, Rosenfeld RG 1993 Demonstration of receptors for insulin-like growth factor binding protein-3 on HS578T human breast cancer cells. J Biol Chem 268:26045-26048
10. Fanayan S, Firth SM, Baxter RC 2002 Signaling through the Smad pathway by insulin-like growth factor binding protein-3 in breast cancer cells: relationship to transforming growth factor-β1 signaling. J Biol Chem 277:7255-7261
11. Kalus W, Zweckstetter M, Renner C, Sanchez Y, Georgescu J, Grol M, Demuth D, Schumacher R, Dony C, Lang K, Holak TA 1998 Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J 17:6558-6572
12. Buckway CK, Wilson EM, Ahlsen M, Bang P, Oh Y, Rosenfeld RG 2001 Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J Clin Endocrinol Metab 86:4943-4950
13. Hong J, Zhang G, Dong F, Rechler MM 2002 Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277:10489-10497
14. Imai Y, Moralez A, Andag U, Clarke JB, Busby WH, Clemmons DR 2000 Substitutions for hydrophobic amino acids in the N-terminal domains of IG-FBP-3 and-5 markedly reduce IGF-I binding and alter their biologic actions. J Biol Chem 275:18188-18194
15. Galanis M, Firth SM, Bond J, Nathanielsz A, Kortt AA, Hudson PJ, Baxter RC 2001 Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. J Endocrinol 169:123-133
16. Booth BA, Boes M, Dake BL, Bar RS 1999 Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3. Am J Physiol 276:E450-E454
17. Lalou C, Lassarre C, Binoux M 1996 A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137:3206-3212
18. Vorwerk P, Yamanaka Y, Spagnoli A, Oh YM, Rosenfeld RG 1998 Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine. J Clin Endocrinol Metab 83:1392-1395
19. Conover CA 1995 Insulin-like growth factor binding protein proteolysis in bone cell models. Prog Growth Factor Res 6:301-309
20. Clemmons DR 1998 Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 140:19-24
21. Lassarre C, Duron F, Binoux M 2001 Use of the ligand immunofunctional assay for human insulin-like growth factor ((IGF) binding protein-3 (IGFBP-3) to analyze IGFBP-3 proteolysis and IGF-I bioavailability in healthy adults, GH-deficient and acromegalic patients, and diabetics. J Clin Endocrinol Metab 86:1942-1952
22. Baxter RC, Bayne ML, Cascieri MA 1992 Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3. J Biol Chem 267:60-65
23. Baxter RC, Martin JL 1986 Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma. J Clin Invest 78:1504-1512
24. Baxter RC, Martin JL, Beniac VA 1989 High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J Biol Chem 264:11843-11848
25. Firth SM, Ganeshprasad U, Baxter RC 1998 Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. J Biol Chem 273:2631-2638
26. Martin JL, Baxter RC 1999 Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells. J Biol Chem 274:16407-16411
27. Bryson JM, Baxter RC 1987 High-affinity receptor for insulin-like growth factor II in rat liver: properties and regulation in vivo. J Endocrinol 113:27-35
28. Holman SR, Baxter RC 1996 Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation. Growth Regul 6:42-47
29. Martin JL, Baxter RC 1986 Insulin-like growth factor binding protein from human plasma. Purification and characterization. J Biol Chem 261:8754-8760
30. Francis GL, Aplin SE, McNeil KA, Milner SJ, Forbes BE, Ross M, Ballard FJ, Wallace JC 1994 Molecular interactions of IGF-I and IGF-II with their binding proteins and receptors. In: Rosenfeld RG, ed. The insulin-like growth factors and their regulatory proteins. Amsterdam: Elsevier; 57-66
31. Heding A, Gill R, Ogawa Y, De Meyts P, Shymko RM 1996 Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3. J Biol Chem 271:13948-13952
32. Twigg SM, Kiefer MC, Zapf J, Baxter RC 1998 Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain. J Biol Chem 273:28791-28798
33. Firth SM, Clemmons DR, Baxter RC 2001 Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding. Endocrinology 142:2147-2150
34. Twigg SM, Kiefer MC, Zapf J, Baxter RC 2000 A central domain binding site in insulin-like growth factor binding protein-5 for the acid-labile subunit. Endocrinology 141:454-457
35. Nakae J, Kido Y, Accili D 2001 Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22:818-835
36. Scott CD, Baxter RC 1987 Purification and immunological characterization of the rat liver insulin-like growth factor-II receptor. Endocrinology 120:1-9
37. Brinkman A, Kortleve DJ, Schuller AG, Zwarthoff EC, Drop SLS 1991 Site-directed mutagenesis of the N-terminal region of IGF binding protein 1: analysis of IGF binding capability. FEBS Lett 291:264-268
38. Brinkman A, Kortleve DJ, Zwarthoff EC, Drop SLS 1991 Mutations in the C-terminal part of insulin-like growth factor (IGF)-binding protein-1 result in dimer formation and loss of IGF binding capacity. Mol Endocrinol 5:987-994
39. Qin XZ, Strong DD, Baylink DJ, Mohan S 1998 Structure-function analysis of the human insulin-like growth factor binding protein-4. J Biol Chem 273:23509-23516
40. Zeslawski W, Beisel HG, Kamionka M, Kalus W, Engh RA, Huber R, Lang K, Holak TA 2001 The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5. EMBO J 20:3638-3644
41. Hashimoto R, Ono M, Fujiwara H, Higashihashi N, Yoshida M, Enjoh-Kimura T, Sakano K 1997 Binding sites and binding properties of binary, and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. J Biol Chem 272:27936-27942
42. Vorwerk P, Hohmann B, Oh Y, Rosenfeld RG, Shymko RM 2002 Binding properties of insulin-like growth factor binding protein-3 (IGFBP-3), IGFBP-3 N-and C-terminal fragments, and structurally related proteins mac25 and connective tissue growth factor measured using a biosensor. Endocrinology 143:1677-1685
43. Forbes BE, Turner D, Hodge SJ, McNeil KA, Forsberg G, Wallace JC 1998 Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain. J Biol Chem 273:4647-4652
44. Ho PJ, Baxter RC 1997 Characterization of truncated insulin-like growth factor-binding protein-2 in human milk. Endocrinology 138:3811-3818
45. Carrick FE, Forbes BE, Wallace JC 2001 BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains. J Biol Chem 276:27120-27128
46. Goren HJ, Kahn CR 1982 Effect of cross-linking agents on insulin associated responses in adipocytes. Can J Biochem 60:987-1000
47. Devi GR, Yang DH, Rosenfeld RG, Oh Y 2000 Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. Endocrinology 141:4171-4179
48. Bernard L, Babajko S, Binoux M, Ricort JM 2002 The amino-terminal region of insulin-like growth factor binding protein-3, (1-95)IGFBP-3, induces apoptosis of MCF-7 breast carcinoma cells. Biochem Biophys Res Commun 293:55-60
49. Salahifar H, Firth SM, Baxter RC, Martin JL 2000 Characterization of an amino-terminal fragment of insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells. Growth Hormone IGF Res 10:367-377
50. Zadeh SM, Binoux M 1997 The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type I IGF receptor gene. Endocrinology 138:3069-3072